Connor, Clark & Lunn Investment Management Ltd. Atara Biotherapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$2.85 - $8.73 $186,934 - $572,609	-65,591 Reduced 62.53%	39,307 $149,000
Q2 2022 Aug 05, 2022	BUY	$4.69 - $9.84 $276,949 - $581,061	59,051 Added 128.8%	104,898 $817,000
Q1 2022 May 12, 2022	BUY	$8.44 - $16.89 $231,002 - $462,279	27,370 Added 148.13%	45,847 $426,000
Q4 2021 Feb 10, 2022	BUY	$14.7 - $19.89 $36,941 - $49,983	2,513 Added 15.74%	18,477 $291,000
Q3 2021 Nov 12, 2021	BUY	$11.99 - $17.9 $191,408 - $285,755	15,964 New	15,964 $286,000
Q2 2020 Aug 13, 2020	SELL	$7.53 - $14.93 $98,018 - $194,343	-13,017 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$5.69 - $17.78 $74,066 - $231,442	13,017 New	13,017 $110,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account